Zobrazeno 1 - 10
of 128
pro vyhledávání: ''
Publikováno v:
Cancer Immunology, Immunotherapy
Bruton’s tyrosine kinase (BTK) is a non-receptor kinase belonging to the Tec family of kinases. The role of BTK in B cell receptor signaling is well defined and is known to play a key role in the proliferation and survival of malignant B cells. Mor
Autor:
Céleste Lebbé, Andrew S. Brohl, Meliessa H. Hennessy, Michele Milella, Patrick Terheyden, Kent C. Shih, Paul Nghiem, Isaac Brownell, Gerald P. Linette, Karl D. Lewis, Shailender Bhatia, Murtuza Bharmal, Omid Hamid, Michael Schlichting, Sandra P. D'Angelo, Janice M. Mehnert, Matthias Hunger
Publikováno v:
Cancer Immunology, Immunotherapy
Background Response rates are primary endpoints in many oncology trials; however, correlation with overall survival (OS) is not uniform across cancer types, treatments, or lines of therapy. This study explored the association between objective respon
Autor:
Klaus Schmierer, Francesca Ammoscato, Helen Lock, David Baker, Zhifeng Mao, Bryan Ceronie, Hilary Longhurst, Benjamin Meir Jacobs, Nicolas Dubuisson, Gavin Giovannoni
Publikováno v:
Journal of Neurology
Background The mechanism of action of oral cladribine, recently licensed for relapsing multiple sclerosis, is unknown. Objective To determine whether cladribine depletes memory B cells consistent with our recent hypothesis that effective, disease-mod
Autor:
Mitsuyoshi Utsugi, Reiko Sakurai, Noriaki Sunaga, Akira Mogi, Yoshio Tomizawa, Tomohito Kuwako, Tomomi Masuda, T. Ishizuka, Kyoichi Kaira, Atsushi Takise, Yosuke Miura, Ryusei Saito, Kimihiro Shimizu, Kaori Seki, Koichi Minato, Masanobu Yamada, Hisao Imai, Shinichi Ishihara, Takeshi Hisada
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose In patients with epidermal growth factor receptor (EGFR)-mutated, advanced, non-small cell lung cancer (NSCLC), common gefitinib-sensitive EGFR mutations that predict a greater response to therapy include the exon 19 deletion and L858R point
Publikováno v:
Cancer Chemotherapy and Pharmacology
Cancer is a complex disease since it is adaptive in such a way that it can promote proliferation and invasion by means of an overactive cell cycle and in turn cellular division which is targeted by antimitotic drugs that are highly validated chemothe
Autor:
Elahe Motevaseli, Alireza Shirazi, Masoud Najafi, Gh. Geraily, M. Heidari, Saeed Rezapoor, F. Norouzi
Radiotherapy has a key role in cancer treatment in more than half of patients with cancer. The management of severe side effects of this treatment modality is a limiting factor to appropriate treatment. Immune system responses play a pivotal role in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9dec20f2aca5f0aecd7213fa76f3882
https://europepmc.org/articles/PMC5425818/
https://europepmc.org/articles/PMC5425818/
Autor:
Daniel Weiss, Liangang Liu, Simon Zhou, Josephine Reyes, Nianhang Chen, Gondi Kumar, Lilia Weiss, Xiaomin Wang, Claudia Kasserra, Maria Palmisano
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Lenalidomide, a weak substrate of P-glycoprotein (P-gp) in vitro, is an oral anticancer drug eliminated predominantly via renal excretion as unchanged compound. The role of P-gp in lenalidomide disposition and the associated clinical relevanc
Autor:
Yasuo Ohkura, Tomokazu Kishiki, Tadahiko Masaki, Takashi Watanabe, Jyunji Furuse, Kouki Ohtsuka, Hiroaki Ohnishi, Masanori Sugiyama
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Since the KRAS mutation is not responsible for all metastatic colorectal cancer (mCRC) patients with resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibody (MoAb) therapy, new predictive and prognostic factors are acti
Autor:
Marijke Stigter-van Walsum, Gerd Stehle, Heiko G. Niessen, Egbert F. Smit, Paul Slobbe, Flavio Solca, Albert D. Windhorst, Guus A.M.S. van Dongen, Alex J. Poot
Publikováno v:
EJNMMI Research
Slobbe, P, Windhorst, A D, Stigter-van Walsum, M, Smit, E F, Niessen, H G, Solca, F, Stehle, G, van Dongen, G A M S & Poot, A J 2015, ' A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [C-11]erlotinib and [F-18]afatinib in lung cancer-bearing mice ', EJNMMI Research, vol. 5, 14 . https://doi.org/10.1186/s13550-015-0088-0
EJNMMI Research, 5:14. Springer Berlin
Slobbe, P, Windhorst, A D, Stigter-van Walsum, M, Smit, E F, Niessen, H G, Solca, F, Stehle, G, van Dongen, G A M S & Poot, A J 2015, ' A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [C-11]erlotinib and [F-18]afatinib in lung cancer-bearing mice ', EJNMMI Research, vol. 5, 14 . https://doi.org/10.1186/s13550-015-0088-0
EJNMMI Research, 5:14. Springer Berlin
Background Tyrosine kinase inhibitors (TKIs) have experienced a tremendous boost in the last decade, where more than 15 small molecule TKIs have been approved by the FDA. Unfortunately, despite their promising clinical successes, a large portion of p
Autor:
Nicolaus Kröger, Thomas Stübig
Publikováno v:
Cancer Immunology ISBN: 9783662464090
Acute lymphoblastic leukaemia (ALL) rises from lymphoid progenitors. ALL cells show vast antigens linked to normal B-cell development and may be used as targets for immunotherapy. Since CD20 is expressed in B-ALL cells, rituximab, an anti-CD20 antibo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6a63216442c537f9e88a026b960f0d20
https://doi.org/10.1007/978-3-662-46410-6_6
https://doi.org/10.1007/978-3-662-46410-6_6